๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma

โœ Scribed by Chisesi, Teodoro; Capnist, Giovanni; de Dominicis, Ennio; Dini, Enrico

Book ID
122940536
Publisher
Elsevier Science
Year
1988
Weight
452 KB
Volume
24
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II study of oral idarubicin (4-d
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
โœ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

Oral 4-demethoxydaunorubicin (idarubicin
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial
โœ Howard S. Hochster; Michael D. Green; Ronald H. Blum; James C. Wernz; James L. S ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› Springer US ๐ŸŒ English โš– 258 KB

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to th